Preincubation with protein synthesis inhibitors protects cortical neurons against oxygen-glucose deprivation-induced death.
Twenty-four hour exposure to cycloheximide produced a concentration-dependent reduction in protein synthesis in mouse cortical cell cultures. Unexpectedly, a 24 h pretreatment with cycloheximide exposure also reduced neuronal vulnerability to subsequent oxygen-glucose deprivation-induced injury, measured both acutely (cell swelling) or after one day (cell lysis). This neuroprotective effect was attenuated if the period of cycloheximide pretreatment was shortened to 8 h, and lost if the pretreatment was shortened to 1 h. A comparable neuroprotective effect was also induced by 24 h pretreatment with another protein synthesis inhibitor, emetine. The neuroprotection induced by pretreatment with cycloheximide or emetine was probably not attributable to reduction of apoptosis: (i) neuronal death under these conditions occurs by N-methyl-D-aspartate receptor-mediated excitotoxic necrosis, not apoptosis; (ii) the same cycloheximide pretreatment did not block staurosporine-induced apoptosis. Also unlikely as an explanation is reduction in postsynaptic vulnerability to excitotoxicity, as death induced by exogenous addition of N-methyl-D-aspartate, kainate, or alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate was little affected by cycloheximide pretreatment. Rather, the protective effect of cycloheximide pretreatment was probably explained, at least in part, by marked reduction in the glutamate release induced by oxygen-glucose deprivation.
Lobner
D
D
Center for the Study of Nervous System Injury, Washington University School of Medicine, St Louis, MO 63110, USA.
Choi
D W
DW
D000818:Animals; D016923:Cell Death / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured; D002540:Cerebral Cortex / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D003513:Cycloheximide / Q000494:pharmacology; D003609:Dactinomycin / Q000494:pharmacology; D016291:Dizocilpine Maleate / Q000494:pharmacology; D004640:Emetine / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005947:Glucose / Q000172:deficiency*; D018698:Glutamic Acid / Q000378:metabolism; D002534:Hypoxia, Brain / Q000473:pathology*; D051379:Mice; D009419:Nerve Tissue Proteins / Q000096:biosynthesis; D009457:Neuroglia / Q000187:drug effects / Q000378:metabolism; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology*
D018691:Excitatory Amino Acid Antagonists; D009419:Nerve Tissue Proteins; D011500:Protein Synthesis Inhibitors; D003609:Dactinomycin; D018698:Glutamic Acid; D016291:Dizocilpine Maleate; D003513:Cycloheximide; D005947:Glucose; D004640:Emetine